Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or primary data synthesis
PubMed 35160128 · doi:10.3390/jcm11030675
What was done
Narrative review synthesizing current literature on the pathogenesis, classification criteria, risk assessment, and therapeutic strategies for obstetric antiphospholipid syndrome (OAPS).
What was found
The abstract reports no quantitative data or numerical effect estimates. It outlines standard therapy as combination treatment with low-dose aspirin and prophylactic low molecular weight heparin. In refractory disease, it reports that adding hydroxychloroquine, low-dose prednisone, or intravenous immunoglobulin improves pregnancy outcomes, while statins and eculizumab are under investigation.
Why it matters
Summarizes clinical classifications and current therapeutic algorithms for mitigating placental injury and recurrent pregnancy loss in antiphospholipid syndrome.
Limits
As a narrative review, it lacks a systematic search protocol, study quality assessment, and pooled quantitative data. No specific effect sizes, sample counts, or patient populations are reported in the abstract.
Cited by
- supports Antiphospholipid syndrome is a hypercoagulable state that during pregnancy can cause placental blood clots and recurrent miscarriages.